سعر الترافيست Ultravist-300‏ 300مجم 50مل فيال 2026

Ultravist-300: iopromide injection, 300 mg iodine/ml (623.4 mg iopromide/ml), 50 ml vial; non-ionic iodinated contrast medium for intra-arterial and intravenous imaging (Bayer).

• Common adverse reactions (>1%): headache, nausea, injection and infusion site reactions, vasodilatation, vomiting, back pain, urinary urgency, chest pain, pain, dysgeusia and abnormal vision.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• No contraindications are listed in the US label (section 4: None); intrathecal use is prohibited by boxed warning.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• BOXED WARNING - NOT FOR INTRATHECAL USE: inadvertent intrathecal administration may cause death, convulsions, cerebral haemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia and brain oedema.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Life-threatening or fatal hypersensitivity reactions (anaphylaxis, bronchospasm, laryngospasm, angioedema, shock) can occur, usually within 1-3 minutes of injection; have emergency equipment and trained personnel available.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute kidney injury including renal failure can occur; minimise dose and ensure hydration.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• MetforminIodinated contrast may increase the risk of metformin-associated lactic acidosis; stop metformin at or before administration in patients with eGFR 30-60 mL/min/1.73 m2, hepatic impairment, alcoholism, heart failure or intra-arterial contrast; re-evaluate eGFR after 48 hours.DailyMed (U.S. National Library of Medicine)
• Radioactive iodine (I-131, I-123)May decrease thyroid uptake of radioactive iodine; avoid thyroid therapy or testing for up to 6 weeks after Ultravist.DailyMed (U.S. National Library of Medicine)
• Protein-bound iodine testDo not perform protein-bound iodine tests for at least 16 days after administration.DailyMed (U.S. National Library of Medicine)

• No data in pregnant women to evaluate drug-associated risk; iopromide crosses the placenta in small amounts; no relevant adverse developmental effects in rat and rabbit studies.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Interruption of breastfeeding is not necessary after Ultravist administration (US label lactation section).International label, same formulation · DailyMed (U.S. National Library of Medicine)